• Study participant must have a diagnosis of moderate to severe plaque psoriasis (PSO) for ≥3 months and:

‣ Body Surface Area (BSA) affected by psoriasis ≥10 %

⁃ Physician's Global Assessment (PGA) score ≥3 (on a scale from 0 to 4)

⁃ Psoriasis Area and Severity Index (PASI) score is ≥12 or

⁃ PASI score is ≥10 and \<12 with at least one of the following:

• \>Clinically relevant facial or scalp involvement

• \>Clinically relevant genital involvement

• \>Clinically relevant palm and sole involvement

• \>Clinically relevant axillary involvement Study participants aged ≥12 years may alternatively have a diagnosis of moderate to severe mixed guttate/plaque PSO with \>50 % to \<80 % guttate lesions for ≥3 months, and must meet the same criteria listed above

• Study participant must be a candidate for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy